Skip Nav Destination
Issues
1 September 2019
-
Cover Image
Cover Image
Diets high in glycemic load (GL) are associated with increased risk for several cancers. In a randomized crossover-controlled feeding trial (see the study beginning on page 567), Garrison and colleagues measured plasma proteins collected at baseline and end of 28-day consumption of the controlled high and low GL diets, using microarrays populated with 3504 antibodies. The authors demonstrate measurable proteomic differences caused by diets in plasma of healthy individuals, and those differences are more robustly detected after stratifying participants by high and low fat mass as determined by dual X-ray absorptiometry. Pathway analysis shows that certain cancer-related pathways (DNA repair, DNA replication, and cell cycle) altered by diet are overrepresented in participants with high fat mass, whereas pathways involved in post-translational protein modification are overrepresented in participants regardless of their fat mass. The results suggest that physiological impact by consumption of diets in differing GL is variable depending on an individual's adiposity. More studies are warranted to test dietary recommendations related to cancer prevention tailored with the additional consideration of fat mass. The cover image depicts a food wheel with different levels of glycemic index, on the background of an image of microarrays, the technology used in this study. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Research Articles
Proteomic Analysis of Plasma Reveals Fat Mass Influences Cancer-Related Pathways in Healthy Humans Fed Controlled Diets Differing in Glycemic Load
Carly B. Garrison; Yuzheng Zhang; Sandi L. Navarro; Timothy W. Randolph; Meredith A.J. Hullar; Mario Kratz; Marian L. Neuhouser; Daniel Raftery; Paul D. Lampe; Johanna W. Lampe
Prostate Stem Cell Antigen Gene Polymorphism Is Associated with H. pylori–related Promoter DNA Methylation in Nonneoplastic Gastric Epithelium
Tomomitsu Tahara; Sayumi Tahara; Noriyuki Horiguchi; Takema Kato; Yasuko Shinkai; Masaaki Okubo; Tsuyoshi Terada; Dai Yoshida; Kohei Funasaka; Mitsuo Nagasaka; Yoshihito Nakagawa; Hiroki Kurahashi; Tomoyuki Shibata; Tetsuya Tsukamoto; Naoki Ohmiya
Upregulation of miR-130b Contributes to Risk of Poor Prognosis and Racial Disparity in African-American Prostate Cancer
Yutaka Hashimoto; Marisa Shiina; Pritha Dasgupta; Priyanka Kulkarni; Taku Kato; Ryan K. Wong; Yuichiro Tanaka; Varahram Shahryari; Shigekatsu Maekawa; Soichiro Yamamura; Sharanjot Saini; Guoren Deng; Z. Laura Tabatabai; Shahana Majid; Rajvir Dahiya
Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2
Amethyst Saldia; Sara H. Olson; Pamela Nunes; Xiaolin Liang; Marguerite L. Samson; Erin Salo-Mullen; Vanessa Marcell; Zsofia K. Stadler; Peter J. Allen; Kenneth Offit; Robert C. Kurtz
Uptake of Cervical Cancer Screening in Ethiopia by Self-Sampling HPV DNA Compared to Visual Inspection with Acetic Acid: A Cluster Randomized Trial
Muluken Gizaw; Brhanu Teka; Friederike Ruddies; Tamrat Abebe; Andreas M. Kaufmann; Alemayehu Worku; Andreas Wienke; Ahmedin Jemal; Adamu Addissie; Eva Johanna Kantelhardt
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.